Navigation Links
On Average, 55 Percent of Surveyed U.S. Asthma Patients Say They Are Likely to Request a Switch to a Drug With Efficacy Comparable to Their Current Medication but Which is Dosed Just Once a Day
Date:12/21/2010

BURLINGTON, Mass., Dec. 21, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an average of 55 percent of surveyed asthma patients in the U.S. report that they are likely or very likely to request a switch to a drug with efficacy that is comparable to their current medication but which is dosed just once a day. The likelihood of requesting this switch increases with worsening disease control, which is likely due to the fact that somewhat-controlled and poorly controlled patients currently use a greater number of drugs and report a greater disease burden.

The new Patient Forum report entitled Patients' Comfort and Familiarity With Current Asthma Treatments May Present Challenges for Emerging Brands also finds that surveyed patients who currently have somewhat-controlled asthma experienced delays in diagnosis and drug treatment compared with surveyed patients who currently have well-controlled asthma. Somewhat-controlled patients are less likely to seek treatment immediately following the onset of symptoms compared with well-controlled patients and are more likely to delay medical attention for seven months or more after they experience symptoms.

"Somewhat-controlled patients are also less likely than well-controlled patients to receive a diagnosis at their first physician visit after the onset of symptoms," said Decision Resources Analyst Amanda Puffer, M.S. "Somewhat-controlled patients are more likely to be diagnosed by a primary care physician (PCP) than well-controlled patients. PCPs may be less comfortable than pulmonologists or allergists with a variety of asthma therapies, which could contribute to the likelihood that patients do not achieve better control of their asthma symptoms."

Regardless of their level of disease control, the findings also reveal that very few patients are likely to request a switch to a treatment with improv
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
4. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
9. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
10. A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
11. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... A live auction will be held to sell over ... other medical facilities around the United States. Various types ... anesthesia, exam and much more. , The live auction ... starting at 9:00am CDT each day. The equipment is at ... Park, IL 60160. Anyone can participate in the auction ...
(Date:5/22/2015)... The world is at a ... intersecting to create new opportunities for leadership in ... at WesternU's 34th annual Commencement Exercises said Wednesday, ... a former San Francisco mayor and likely 2018 ... graduation ceremony for WesternU's colleges of Allied Health ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... , SUNDAY, May 13 (HealthDay News) -- A new type ... people who have lost their vision due to degenerative eye ... research with rats. The system uses tiny solar panel-like ... a specially designed pair of goggles equipped with a miniature ...
... new study has found that, contrary to current thinking, taking ... a person,s risk of developing colorectal cancer. Published early online ... Cancer Society, the study also revealed that even long-term use ... cancer risk. In recent years, researchers have thought that ...
... , THURSDAY, May 10 (HealthDay News) -- An advisory panel ... approval of the weight-loss medication lorcaserin, even though concerns remain ... give the nod to the drug, lorcaserin would become the ... decade. The FDA is not bound to follow the advice ...
... is the leading cause of death among children under 5, ... Johns Hopkins Bloomberg School of Public Health. They examined the ... found that 64 percent were attributable to infectious causes and ... the May issue of the Lancet , suggest a ...
... who are making a big difference in the highly ... two early-stage discovery awards from Grand Challenges Explorations, an ... The global health projects will focus on creating ... for low-cost, in-home diagnoses. The prestigious awards ...
... reduced mobility now have access to specialized exercise equipment ... between the University of Alberta and the Spinal Cord ... functional electrical stimulation (FES) rehabilitation therapy machines are now ... the Faculty of Physical Education and Recreation at the ...
Cached Medicine News:Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Blood pressure drugs don't protect against colorectal cancer 2Health News:FDA Panel Gives Blessing to New Weight-Loss Drug 2Health News:Pneumonia and preterm birth complications are the leading causes of childhood death 2Health News:2 Grand Challenges Explorations grants for global health 2Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: